Compile Data Set for Download or QSAR
Report error Found 61 Enz. Inhib. hit(s) with all data for entry = 3135
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392703(3-((4-((4-(3-(3-(tert-Butyl)-1-(3-((dimethylphosph...)
Affinity DataIC50: 4nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392690(3-Ethynyl-5-((4-((4-(3-(3-isopropyl-1-(p-tolyl)-1H...)
Affinity DataIC50: 11nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392694(US10301288, Example 5)
Affinity DataIC50: 13nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392692(US10301288, Example 3)
Affinity DataIC50: 14nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392705(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 15nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392698(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 15nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392695(US10301288, Example 12 | US10301288, Example 6)
Affinity DataIC50: 17nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392696(US10301288, Example 7)
Affinity DataIC50: 18nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392704(3-((4-((4-(3-(3-(tert-Butyl)-1-(3-((dimethylphosph...)
Affinity DataIC50: 18nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392693(US10301288, Example 4)
Affinity DataIC50: 19nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392697(US10301288, Example 8)
Affinity DataIC50: 20nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392703(3-((4-((4-(3-(3-(tert-Butyl)-1-(3-((dimethylphosph...)
Affinity DataIC50: 20nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392702(3-((4-((4-(3-(3-(tert-Butyl)-1-(2,4-dimethoxypheny...)
Affinity DataIC50: 21nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392690(3-Ethynyl-5-((4-((4-(3-(3-isopropyl-1-(p-tolyl)-1H...)
Affinity DataIC50: 25nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392699(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 25nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392705(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 27nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392692(US10301288, Example 3)
Affinity DataIC50: 30nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392690(3-Ethynyl-5-((4-((4-(3-(3-isopropyl-1-(p-tolyl)-1H...)
Affinity DataIC50: 30nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392694(US10301288, Example 5)
Affinity DataIC50: 33nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392694(US10301288, Example 5)
Affinity DataIC50: 34nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392704(3-((4-((4-(3-(3-(tert-Butyl)-1-(3-((dimethylphosph...)
Affinity DataIC50: 34nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392698(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 35nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392692(US10301288, Example 3)
Affinity DataIC50: 39nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392695(US10301288, Example 12 | US10301288, Example 6)
Affinity DataIC50: 42nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392693(US10301288, Example 4)
Affinity DataIC50: 46nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392699(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 48nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392693(US10301288, Example 4)
Affinity DataIC50: 50nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392690(3-Ethynyl-5-((4-((4-(3-(3-isopropyl-1-(p-tolyl)-1H...)
Affinity DataIC50: 50nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392690(3-Ethynyl-5-((4-((4-(3-(3-isopropyl-1-(p-tolyl)-1H...)
Affinity DataIC50: 52nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392704(3-((4-((4-(3-(3-(tert-Butyl)-1-(3-((dimethylphosph...)
Affinity DataIC50: 57nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392696(US10301288, Example 7)
Affinity DataIC50: 88nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392703(3-((4-((4-(3-(3-(tert-Butyl)-1-(3-((dimethylphosph...)
Affinity DataIC50: 88nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392695(US10301288, Example 12 | US10301288, Example 6)
Affinity DataIC50: 96nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392698(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 98nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392697(US10301288, Example 8)
Affinity DataIC50: 104nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392699(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 110nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392697(US10301288, Example 8)
Affinity DataIC50: 120nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392702(3-((4-((4-(3-(3-(tert-Butyl)-1-(2,4-dimethoxypheny...)
Affinity DataIC50: 123nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392696(US10301288, Example 7)
Affinity DataIC50: 237nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392690(3-Ethynyl-5-((4-((4-(3-(3-isopropyl-1-(p-tolyl)-1H...)
Affinity DataIC50: 370nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392702(3-((4-((4-(3-(3-(tert-Butyl)-1-(2,4-dimethoxypheny...)
Affinity DataIC50: 370nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392703(3-((4-((4-(3-(3-(tert-Butyl)-1-(3-((dimethylphosph...)
Affinity DataIC50: 402nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392705(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 646nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392700(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 766nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392700(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 1.21E+3nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392700(3-((4-((4-(3-(3-(tert-Butyl)-1-(4-(dimethylamino)p...)
Affinity DataIC50: 1.21E+3nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392695(US10301288, Example 12 | US10301288, Example 6)
Affinity DataIC50: 1.70E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392696(US10301288, Example 7)
Affinity DataIC50: 2.02E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392702(3-((4-((4-(3-(3-(tert-Butyl)-1-(2,4-dimethoxypheny...)
Affinity DataIC50: 2.13E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Topivert Pharma

US Patent
LigandPNGBDBM392697(US10301288, Example 8)
Affinity DataIC50: 2.89E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 61 total ) | Next | Last >>
Jump to: